BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 33109540)

  • 1. WNT Signaling Driven by R-spondin 1 and LGR6 in High-grade Serous Ovarian Cancer.
    Lee S; Jun J; Kim WJ; Tamayo P; Howell SB
    Anticancer Res; 2020 Nov; 40(11):6017-6028. PubMed ID: 33109540
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Both fallopian tube and ovarian surface epithelium are cells-of-origin for high-grade serous ovarian carcinoma.
    Zhang S; Dolgalev I; Zhang T; Ran H; Levine DA; Neel BG
    Nat Commun; 2019 Nov; 10(1):5367. PubMed ID: 31772167
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synchronous profiling of mRNA N6-methyladenosine modifications and mRNA expression in high-grade serous ovarian cancer: a pilot study.
    Yang L; Liu J; Jin Y; Xing J; Zhang J; Chen X; Yu A
    Sci Rep; 2024 May; 14(1):10427. PubMed ID: 38714753
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exploiting the Receptor-Binding Domains of R-Spondin 1 to Target Leucine-Rich Repeat-Containin G-Coupled Protein Receptor 5-Expressing Stem Cells in Ovarian Cancer.
    Wong C; Mulero MC; Barth EI; Wang K; Shang X; Tikle S; Rice C; Gately D; Howell SB
    J Pharmacol Exp Ther; 2023 May; 385(2):95-105. PubMed ID: 36849411
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CST2 promotes cell proliferation and regulates cell cycle by activating Wnt-β-catenin signalling pathway in serous ovarian cancer.
    Wang X; Zhao S; Guo Y; Wang C; Han S; Wang X
    J Obstet Gynaecol; 2024 Dec; 44(1):2363515. PubMed ID: 38864487
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NB compounds are potent and efficacious FOXM1 inhibitors in high-grade serous ovarian cancer cells.
    Liu C; Vorderbruggen M; Muñoz-Trujillo C; Kim SH; Katzenellenbogen JA; Katzenellenbogen BS; Karpf AR
    J Ovarian Res; 2024 May; 17(1):94. PubMed ID: 38704607
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HMGA2 and high-grade serous ovarian carcinoma.
    Wu J; Wei JJ
    J Mol Med (Berl); 2013 Oct; 91(10):1155-65. PubMed ID: 23686260
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Integrative analysis reveals early epigenetic alterations in high-grade serous ovarian carcinomas.
    Machino H; Dozen A; Konaka M; Komatsu M; Nakamura K; Ikawa N; Shozu K; Asada K; Kaneko S; Yoshida H; Kato T; Nakayama K; Saloura V; Kyo S; Hamamoto R
    Exp Mol Med; 2023 Oct; 55(10):2205-2219. PubMed ID: 37779141
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Replication stress and defective checkpoints make fallopian tube epithelial cells putative drivers of high-grade serous ovarian cancer.
    Galhenage P; Zhou Y; Perry E; Loc B; Fietz K; Iyer S; Reinhardt F; Da Silva T; Botchkarev V; Chen J; Crum CP; Weinberg RA; Pathania S
    Cell Rep; 2023 Oct; 42(10):113144. PubMed ID: 37729060
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BNC2 is a putative tumor suppressor gene in high-grade serous ovarian carcinoma and impacts cell survival after oxidative stress.
    Cesaratto L; Grisard E; Coan M; Zandonà L; De Mattia E; Poletto E; Cecchin E; Puglisi F; Canzonieri V; Mucignat MT; Zucchetto A; Stocco G; Colombatti A; Nicoloso MS; Spizzo R
    Cell Death Dis; 2016 Sep; 7(9):e2374. PubMed ID: 27899818
    [TBL] [Abstract][Full Text] [Related]  

  • 11. R-spondin-1 induces Axin degradation via the LRP6-CK1ε axis.
    Tan L; Yan M; Su Z; Wang H; Li H; Zhao X; Liu S; Zhang L; Sun Q; Lu D
    Cell Commun Signal; 2024 Jan; 22(1):14. PubMed ID: 38183076
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Tyrosine Kinase Adaptor Protein FRS2 Is Oncogenic and Amplified in High-Grade Serous Ovarian Cancer.
    Luo LY; Kim E; Cheung HW; Weir BA; Dunn GP; Shen RR; Hahn WC
    Mol Cancer Res; 2015 Mar; 13(3):502-9. PubMed ID: 25368431
    [TBL] [Abstract][Full Text] [Related]  

  • 13. WNT enhancing signals in pancreatic cancer are transmitted by LGR6.
    Wang J; Koch DT; Hofmann FO; Härtwig D; Beirith I; Janssen KP; Bazhin AV; Niess H; Werner J; Renz BW; Ilmer M
    Aging (Albany NY); 2023 Sep; 15(20):10897-10914. PubMed ID: 37770230
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TP53 loss initiates chromosomal instability in fallopian tube epithelial cells.
    Bronder D; Tighe A; Wangsa D; Zong D; Meyer TJ; Wardenaar R; Minshall P; Hirsch D; Heselmeyer-Haddad K; Nelson L; Spierings D; McGrail JC; Cam M; Nussenzweig A; Foijer F; Ried T; Taylor SS
    Dis Model Mech; 2021 Nov; 14(11):. PubMed ID: 34569598
    [TBL] [Abstract][Full Text] [Related]  

  • 15. KLF7: a new candidate biomarker and therapeutic target for high-grade serous ovarian cancer.
    De Donato M; Babini G; Mozzetti S; Buttarelli M; Ciucci A; Arduini G; De Rosa MC; Scambia G; Gallo D
    J Exp Clin Cancer Res; 2020 Nov; 39(1):265. PubMed ID: 33250051
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of R-spondin proteins in cancer biology.
    Ter Steege EJ; Bakker ERM
    Oncogene; 2021 Nov; 40(47):6469-6478. PubMed ID: 34663878
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HCK Promotes High-Grade Serous Ovarian Cancer Tumorigenesis through CD44 and NOTCH3 Signaling.
    Khella CA; Franciosa L; Rodirguez-Rodriguez L; Rajkarnikar R; Mythreye K; Gatza ML
    Mol Cancer Res; 2023 Oct; 21(10):1037-1049. PubMed ID: 37342066
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epigenetic analysis of the Notch superfamily in high-grade serous ovarian cancer.
    Ivan C; Hu W; Bottsford-Miller J; Zand B; Dalton HJ; Liu T; Huang J; Nick AM; Lopez-Berestein G; Coleman RL; Baggerly KA; Sood AK
    Gynecol Oncol; 2013 Mar; 128(3):506-11. PubMed ID: 23200915
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of candidate factors associated with the metastasis and progression of high-grade serous ovarian cancer.
    Liu H; Zhou L; Cheng H; Wang S; Luan W; Cai E; Ye X; Zhu H; Cui H; Li Y; Chang X
    Chin Med J (Engl); 2023 Dec; 136(24):2974-2982. PubMed ID: 37284741
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Unraveling tumor-immune heterogeneity in advanced ovarian cancer uncovers immunogenic effect of chemotherapy.
    Jiménez-Sánchez A; Cybulska P; Mager KL; Koplev S; Cast O; Couturier DL; Memon D; Selenica P; Nikolovski I; Mazaheri Y; Bykov Y; Geyer FC; Macintyre G; Gavarró LM; Drews RM; Gill MB; Papanastasiou AD; Sosa RE; Soslow RA; Walther T; Shen R; Chi DS; Park KJ; Hollmann T; Reis-Filho JS; Markowetz F; Beltrao P; Vargas HA; Zamarin D; Brenton JD; Snyder A; Weigelt B; Sala E; Miller ML
    Nat Genet; 2020 Jun; 52(6):582-593. PubMed ID: 32483290
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.